Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7130 in Solid Tumors
NCT03444701Phase 1Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of E7130 in solid tumor, squamous cell carcinoma of the head and neck (HNSCC) and urothelial carcinoma (UC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Treatment Emergent Adverse Events at 82.5 months. Started Feb 2018; status: terminated.
02
Drugs
E7130
03
Conditions
solid tumorsquamous cell carcinoma of the head and neck (HNSCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03444701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444701.